Our mission: develop fully human monoclonal antibodies for the adjunctive treatment of severe hospital acquired infections
We are a biotech company focused on the discovery and development of novel, fully human monoclonal antibodies for the prevention and treatment of serious bacterial and viral infections in the hospital setting.
The MabIgX® technology for the generation and selection of fully human monoclonal antibodies (mAbs) allows the harnessing of the power of the human immune system and transforms it into highly effective therapeutic antibodies for the treatment of life threatening infections. The unique technology in combination with focused scientific and clinical expertise had enabled Kenta Biotech to rapidly move innovative antibody therapies from bench to high medical need patients.
Kenta Biotech AG